article thumbnail

Xolair amplifies reach after FDA approval for treating food allergies 

Pharmaceutical Technology

Xolair is the first FDA-approved drug to reduce allergic reactions in people with one or more food allergies, as per Roche’s announcement.

Allergies 236
article thumbnail

Nestlé divests peanut allergy treatment Palforzia to Stallergenes Greer

Pharmaceutical Technology

Nestlé has sold its peanut allergy drug Palforzia to Swiss biopharma Stallergenes Greer harma, concluding a year-long strategic review.

Allergies 299
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cat Allergy drugs in development, 2023

Pharmaceutical Technology

GlobalData tracks 4 drugs in development for Cat Allergy by four companies/universities/institutes. The top development phase for Cat Allergy is preclinical, with two drugs in that stage.

Allergies 130
article thumbnail

Allergen for Peanut Allergy by ALK-Abello for Peanut Allergy: Likelihood of Approval

Pharmaceutical Technology

Allergen for Peanut Allergy is under clinical development by ALK-Abello and currently in Phase II for Peanut Allergy.

Allergies 100
article thumbnail

Ligelizumab by Novartis for Food Allergy: Likelihood of Approval

Pharmaceutical Technology

Ligelizumab is under clinical development by Novartis and currently in Phase III for Food Allergy.

Allergies 187
article thumbnail

FDA fast tracks Alladapt’s multi-food allergy immunotherapy

Pharmaceutical Technology

The fast track designation for the paediatric multi-food allergy therapy ADP101 was based on the Phase I/II data.

Allergies 147
article thumbnail

Grass Pollen Allergy drugs in development, 2023

Pharmaceutical Technology

GlobalData tracks 11 drugs in development for Grass Pollen Allergy by ten companies/universities/institutes. The top development phase for Grass Pollen Allergy is phase ii, with six drugs in that stage.

Allergies 130